[HTML][HTML] Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
X Wang, CQ Sacramento, S Jockusch… - Communications …, 2022 - nature.com
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture.
X Wang, CQ Sacramento, S Jockusch… - Communications …, 2022 - search.ebscohost.com
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture.
X Wang, CQ Sacramento, S Jockusch, OA Chaves… - 2022 - cabidigitallibrary.org
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
[引用][C] Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
X Wang, CQ Sacramento, S Jockusch, OA Chaves… - 2022 - agris.fao.org
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and
demonstrates COVID-19 therapeutic potential in viral cell culture Food and Agriculture …
demonstrates COVID-19 therapeutic potential in viral cell culture Food and Agriculture …
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
X Wang, CQ Sacramento, S Jockusch… - Communications …, 2022 - pubmed.ncbi.nlm.nih.gov
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
X Wang, CQ Sacramento, S Jockusch, OA Chaves… - bioRxiv, 2021 - biorxiv.org
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
X Wang, CQ Sacramento, S Jockusch, OA Chaves… - 2021 - arca.fiocruz.br
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
[HTML][HTML] Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
X Wang, CQ Sacramento, S Jockusch, OA Chaves… - 2021 - europepmc.org
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
[HTML][HTML] Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
X Wang, CQ Sacramento, S Jockusch… - Communications …, 2022 - ncbi.nlm.nih.gov
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
such as Remdesivir that are incorporated into the viral RNA during replication, reducing the …
[PDF][PDF] Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
X Wang, CQ Sacramento, S Jockusch, OA Chaves… - scienceopen.com
Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as
Potential COVID-19 Therapeutics Page 1 1 Combination of Antiviral Drugs to Inhibit SARS-CoV-2 …
Potential COVID-19 Therapeutics Page 1 1 Combination of Antiviral Drugs to Inhibit SARS-CoV-2 …